Search
In recent times, leading tech enterprises including OpenAI, Amazon Web Services (AWS), and NVIDIA have been fervently making inroads into the new drug discovery arena. OpenAI has unveiled GPT-Rosalind, a sophisticated large-scale model tailored specifically for the life sciences domain. AWS has rolled out Amazon Bio Discovery, an AI-driven drug development application based on intelligent agents. Meanwhile, NVIDIA has forged partnerships with numerous institutions to broaden the protein structure database. These endeavors, with AI at their heart, are fundamentally transforming the conventional paradigm of new drug discovery, sparking an efficiency revolution that spans the entire journey from target identification and molecular design to experimental validation. Intelligent technologies are thus comprehensively fueling pharmaceutical innovation.
-
C114 Communication Network -
Communication Home
